Previous Close | 2.9100 |
Open | 2.9600 |
Bid | 0.0000 x 800 |
Ask | 0.0000 x 800 |
Day's Range | 2.8700 - 3.0300 |
52 Week Range | 2.2600 - 17.3900 |
Volume | |
Avg. Volume | 220,001 |
Market Cap | 101.756M |
Beta (5Y Monthly) | 3.28 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -3.0750 |
Earnings Date | May 12, 2022 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 18.80 |
Subscribe to Yahoo Finance Plus to view Fair Value for RZLT
Announced a $130 million registered direct offering and concurrent private placement Positive topline results from Phase 2b RIZE study of RZ358 exceeded expectations and demonstrated highly significant reduction in hypoglycemia events, ~75% at anticipated therapeutic doses Positive data from Phase 1b multiple-ascending dose study of RZ402 enable Phase 2 proof-of-concept study initiation later this year REDWOOD CITY, Calif., May 12, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinic
Company to Host Analyst and Investor Conference Call on Wednesday, May 4 at 4:30 p.m. ETREDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced that management will be hosting a corporate update call. The call will highlight recent pipeline advancements and continued
REDWOOD CITY, Calif., May 04, 2022 (GLOBE NEWSWIRE) -- Rezolute, Inc. (Nasdaq: RZLT), a clinical-stage biopharmaceutical company dedicated to developing transformative therapies with the potential to disrupt current treatment paradigms for devastating metabolic diseases, today announced the closing of its previously announced underwritten registered direct offering of an aggregate of 18,026,315 shares of its common stock at an offering price of $3.80 per share, and, to certain investors in lieu